Project summary:

The CORONAVIT trial is a randomised controlled trial of 6200 people to evaluate the impact of vitamin D replacement on incidence and severity of acute respiratory infections, with a major focus on COVID-19. It is nested within the COVIDENCE UK study. All participants who were vaccinated during participation in the trial were offered anti-S antibody testing via dried blood spot; additionally a subset of 121 participants gave a venous blood sample post-vaccination for determination of neutralising antibody titres and antigen-specific T cell responses to SARS-CoV-2 peptides. These data will be analysed to determine whether vitamin D influences vaccine-induced host responses to SARS-CoV-2.


Barts Charity, Pharma Nord Ltd, the Fischer Family Trust, Dangoor Education, DSM Nutritional Products Ltd, the Karl R Pfleger Foundation, the AIM Foundation, Synergy Biologics Ltd, Thornton & Ross Ltd, Warburtons Ltd, Mr Matthew Isaacs (personal donation), and Hyphens Pharma Ltd.

Leader researcher:

Professor Adrian Martineau

Lead institution:

Queen Mary University of London

Vaccine type:


Recruitment for clinical trial open: